Project Grant R01CA309046
Award Date 8/1/26
Completion Date 7/31/31
Dollars Obligated $653K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10029, USA
Similar Awards
- The National Cancer Institute awarded the Sloan-Kettering Institute for Cancer Research $252,023 on September 3, 2026, under the Cancer Research Manpower program (CFDA 93.398) to adapt an evidence-based goals-of-care communication intervention for adolescent and young adult cancer patients (ages 15–39). The project addresses poor end-of-life outcomes in this population, including high rates of futile aggressive care interventions in the final month of life and low hospice enrollment. Current...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $745,458 on July 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop and test a digital intervention that uses patient portals to improve person-centered communication between cancer patients and oncology clinicians. The PERSON intervention comprises three automated, scalable components: a portal-enabled assessment tool (a 14-item questionnaire capturing patient information...
- The National Cancer Institute awarded The Trustees of Columbia University in the City of New York $140,364 on August 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support the K99 phase of research developing cancer survivor hospitalization risk assessment through multimodal analysis of care manager–patient communications in managed long-term care settings. The project, "The CHAMP Study: Cancer Survivor Hospitalization Risk Assessment Through Multimodal Patient-Care...
- The National Institutes of Health National Cancer Institute awarded Icahn School of Medicine at Mount Sinai $628,394 on May 8, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop and validate a patient-derived organoid with tumor microenvironment (PDOT) co-culture system for modeling therapeutic responses in intrahepatic cholangiocarcinoma. The recipient will establish a precision preclinical platform that simultaneously reconstitutes intrahepatic cholangiocarcinoma...
- The National Institutes of Health National Cancer Institute awarded the Sloan-Kettering Institute For Cancer Research $731,503 on June 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a randomized controlled trial of brief behavioral activation for older adult cancer survivors. The research addresses depression among cancer survivors aged 65 and older, a population expected to comprise 73 percent of all cancer survivors by 2040, with up to 35 percent...
- The National Cancer Institute awarded Icahn School of Medicine at Mount Sinai $697,131 on May 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate myeloid-stromal interactions that drive immune suppression in colorectal cancer and to evaluate therapeutic strategies targeting these pathways. The research addresses the immunological resistance of microsatellite-stable colorectal cancer to immune checkpoint blockade, particularly in patients with liver metastases. The...
- The National Cancer Institute awarded The Washington University $656,181 on June 19, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct the Communication and Hospice Online with Optimal Support and Engagement (CHOOSE) study. The CHOOSE initiative is a multisite, theoretically informed intervention designed to strengthen facilitator communication strategies in online support groups serving family caregivers of hospice cancer patients. The study aims to...
- The National Cancer Institute awarded Icahn School of Medicine at Mount Sinai $711,272 on July 1, 2026, for research to identify optimal lung cancer screening strategies in people living with HIV under the Cancer Treatment Research program (CFDA 93.395). The research addresses lung cancer mortality among people with HIV, which now represents the leading source of cancer deaths in this population. Most lung cancers in people with HIV are diagnosed at late stages with poor survival outcomes. The...
- The National Cancer Institute awarded Yale University $316,200 on August 6, 2026, under the Cancer Research Manpower program (CFDA 93.398) to establish and operate the Survivorship Care Academy, a five-year educational initiative training oncology clinicians to develop and enhance clinical survivorship programs aligned with National Cancer Institute standards. The Academy will deliver a four-day annual in-residence workshop to 125 clinicians over five years (25 per year) covering key...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $747,660 on June 2, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct the RADIANT trial, which builds evidence for a scalable remote patient monitoring and integrative medicine intervention delivered via telemedicine to reduce hospital readmissions in medical oncology patients discharged to home. The trial addresses the 12-week readmission rate for cancer patients, which ranges...